Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Completed · Phase 4

Conditions studied: Cost Sharing, Acute Coronary Syndrome

In brief

Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess the impact of copayment reduction by equalizing the copayment of clopidogrel and ticagrelor. ARTEMIS will assess prescribing patterns, patient medication adherence, and clinical outcomes up to one year. We hypothesize that reducing out--of--pocket cost for P2Y12 receptor inhibitor will lead to improved adherence. Additionally, copayment reduction of both generic and brand antiplatelet agents may lead to a reduction in MACE risk. This is in part due to greater adherence to an evidence--based secondary prevention medication. Additionally the reduction in MACE may reflect greater selection of a more potent antiplatelet agent that has been shown to reduce MACE in randomized clinical trials, as provider choice of antiplatelet therapy will be primarily driven by risk- benefit assessment rather than the cost burden to the patient.

Key facts

Study ID

NCT02406677

Run by

AstraZeneca

People needed

11001

Starts

2015-06-05

Expected to finish

2017-10-23

Last updated by the study team

2019-10-01

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients are eligible to be included in the study if they meet all of the following criteria:
• are ≥ 18 years of age
• have been diagnosed with STEMI or NSTEMI during the index hospitalization
• be treated with a P2Y12 receptor inhibitor at the time of enrollment
• have U.S. based health insurance coverage with prescription drug benefit
• have been fully informed and are able to provide written consent for longitudinal follow-up

You may not qualify if…

• Patients are excluded if they meet any of the following criteria:
• have a history of prior intracranial hemorrhage
• have any contraindications to P2Y12 receptor inhibitor therapy at discharge
• involvement in another research study that specifies the type and duration of P2Y12 receptor inhibitor use within the next 12 months.
• have a life expectancy of less than one year
• have plans to move outside the US in the next year

Where it is running

• Research Site — Huntsville, Alabama, United States
• Research Site — Mobile, Alabama, United States
• Research Site — Mobile, Alabama, United States
• Research Site — Anchorage, Alaska, United States
• Research Site — Cottonwood, Arizona, United States
• Research Site — Flagstaff, Arizona, United States
• Research Site — Phoenix, Arizona, United States
• Research Site — Fayetteville, Arkansas, United States
• Research Site — Fort Smith, Arkansas, United States
• Research Site — Jonesboro, Arkansas, United States
• Research Site — Little Rock, Arkansas, United States
• Research Site — Escondido, California, United States
• Research Site — Huntington Beach, California, United States
• Research Site — Loma Linda, California, United States
• Research Site — Los Angeles, California, United States
• Research Site — Los Angeles, California, United States
• Research Site — Northridge, California, United States
• Research Site — Pasadena, California, United States
• Research Site — Riverside, California, United States
• Research Site — Salinas, California, United States
• Research Site — Stockton, California, United States
• Research Site — Thousand Oaks, California, United States
• Research Site — Torrance, California, United States
• Research Site — Vista, California, United States
• Research Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.